The Neurotech Investing and Partnering Conference 2014

Boston, Massachusetts
Wednesday, April 23, 2014

Ritz-Carlton Boston, MA

  Wednesday April 23, 2014
 7:30 Breakfast and Registration
 8:30 Welcome: Neurotech Trends and NIO Initiatives

NIO and NINDS provide an update on ongoing initiatives and programs to support the Neurotech industry including nondilutive funding and emerging partnering opportunities.

Zack Lynch
, Executive Director, Neurotechnology Industry Organization
 8:40 Emerging Partnering and Nondilutive Funding Opportunities
  Rajesh Ranganathan, Director for Translational Research, NIH/NINDS
 9:00 Investing in Neurotech Panel
  A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Bruce Leuchter, Healthcare Investment Banking, Credit Suisse

Kevin Bitterman, Partner, Polaris Partners

Rajeev Shah, Partner, RA Capital Management

Ali Behbahani, Partner, New Enterprise Associates

Peter Young, Executive in Residence, A.M.Pappas & Associates

10:00 Networking and Refreshment Break
10:30  Alzheimer's and Cognitive Disorders
  As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?  Can earlier or more accurate diagnosis improve outcomes?

Moderator: Stacie Weninger, Executive Director, Fidelity Biosciences Research Initiative

Eyal Baror, CEO and Founder, Neuronix

Dirk Beher, CEO and Founder, ASCENeuron

Daniel Chain, CEO and Founder, CereSpir

Paul Hartung, CEO, Cognoptix

Carmela Abraham, Founder, Klogene Therapeutics

2:00 Internal and External Research & Development
  What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?

Moderator:  Peter Young, Executive in Residence, A.M.Pappas & Associates

Ajay Verma,
VP Translational Neurology, Biogen Idec

Rivka Riven Kreitman, Senior VP, Head of Search, Evaluation & Alliance Management, Teva Pharmaceuticals

Sherrie Perkins
, VP Marketing and New Business Development, Cyberonics

Jason Kralic, Head of Neuroscience Business Development,

Networking and Refreshment Break
3:30 New Developments in Chronic and Neuropathic Pain
  Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in chronic and neuropathic pain. What emerging treatment options are there on the horizon?

Moderator: Kiran Reddy, Associate Partner, Third Rock Ventures

Barry Yomtov, Chief Technical Officer, Advastim

Ben Pless, CEO, Autonomic Technologies

Marom Bikson, CEO and Founder, Soterix Medical

Charles Yeomans, CEO, Trigemina

 4:30 Strategies in CNS Drug and Device Development
  Intelligent trial design, fundraising, and business development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement. Case studies will demonstrate lessons learned in Alzheimer's, Parkinson's, depression, pain and more.

Moderator: David Lowe, CEO, NeuroAssets

Bob Switzer, CEO, NeuroScience Associates

Simone Braggio, Director, Drug Design and Discovery, Aptuit

Tina Soulis, General Manager, Neuroscience Trials Australia
Networking Reception
  Thursday April 24, 2014
Continental Breakfast & Registration
 8:30 Keynote: Congressman Chakah Fattah on the Brain Initiative
 9:00 Partnering and Licensing in Neurotech Panel
  Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions?  With big pharma paying more attention to neurodiagnostics, what kinds of deals and partnerships can we expect in 2014 and 2015?

Moderator: Christine de los Reyes, VP Strategic Planning and Business Development, Alopexx Enterprises

Jeffrey Nye
, Vice President, Neuroscience Innovation and Partnership Strategy, Janssen Pharmaceuticals, Johnson & Johnson Innovation

Jeffrey Erb,
Senior Director of Business Development, Alliances and IP Management, Medtronic Neuromodulation

Jay Kranzler, Global Head, External R&D, Neuroscience, Pfizer

David Chapman, Senior Director Scientific Licensing, Shire

Networking and Refreshment Break
10:30 Frontiers in Neurotechnology
  In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets including asthma, migraine, psychiatry, and epilepsy. Closed loop systems create the promise of reduced side effects and more targeted treatment.  New technology is yielding benefits in neurodiagnostics. Software solutions are tackling neuropsychiatric markets. Don't miss this preview of next generation products and companies.

Moderator:  Mark Chin, Vice President, Longitude Capital

Frank McEachern, CEO, Microtransponder, Inc.

Corey McCann, CEO, Pear Therapeutics

Ana Maiques
, CEO,

Janne Huhtala, CEO, Nexstim Oy

12:00 Lunch 
1:30 Parkinson's and Other Movement Disorders
  Current treatments for movement disorders can improve functioning but suffer from side effects and “off” period especially as the disease progresses.  What is in the pipeline to address these issues?  Can disease modifying treatments alter the course of disease?  Can diagnostics improve treatment?

Moderator: Manuel Lopez Figueroa, Vice President, Bay City Capital

Glenn Batchelder,
CEO and co-founder, Civitas Therapeutics

Mark Pykett, CEO, Navidea Biosciences

Kevin Gorman, CEO, Neurocrine Biosciences

Randall Moreadith, CEO, Serina

2:30 Next Generation Psychiatry
  Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market.  What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?

Moderator: Thomas Sager, Director, Search & Scientific Assessment, Corporate Business Development & Strategy, H. Lundbeck A/S

Daniel Grau, President, Heptares

Blake Paterson, CEO, Cerecor

Evian Gordon, CEO and founder, Brain Resource

Eric Meier, President and CEO, Cervel Neurotech

3:30 Refreshments
Traumatic Injury: Stroke and TBI
  Drugs and devices are on the horizon to improve outcomes of patients with acute traumatic injury. Novel strategies allow some to succeed where many have failed.

Moderator: Teo Forcht Dagi, Harvard Medical School, Queen's University Belfast, and Broadview Ventures

Eamon Brady, CEO, Neuravi

Fred Colen, CEO, Benechill

David Hagedorn, CEO, Evoke Neuroscience

Sven Jacobson, CEO, Remedy Pharmaceuticals

4:45 Conference Concludes



Contact Information